Development of a Novel Location-Based Assessment of Sensory Symptoms in Cancer Patients: Preliminary Reliability and Validity Assessment

Journal of Pain and Symptom Management

Volumn 37, Issue 5, 2009, Pages 848-862

  Burkey, Adam R ^a   Kanetsky, Peter A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer pain; description; location; neuropathy; quality of life; reliability

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER PAIN; CANCER PATIENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CRONBACH ALPHA COEFFICIENT; FEMALE; HEAD AND NECK CANCER; HUMAN; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; STATISTICAL SIGNIFICANCE; VALIDITY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEURALGIA; PAIN; PAIN MEASUREMENT; PILOT PROJECTS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 67349144157     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2008.05.013     Document Type: Article

References (62)

1. Holen J.C., Hjermstad M.J., Loge J.H., et al. Pain assessment tools: is the content appropriate for use in palliative care?. J Pain Symptom Manage 32 6 (2006) 567-580
2. Jensen M.P. The validity and reliability of pain measures in adults with cancer. J Pain 4 1 (2003) 2-21
3. Jensen M.P., Dworkin R.H., Gammaitoni A.R., et al. Do pain qualities and spatial characteristics make independent contributions to interference with physical and emotional functioning?. J Pain 7 9 (2006) 644-653
4. Grond S., Zech D., Diefenbach C., Radbruch L., and Lehmann K.A. Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain 64 1 (1996) 107-114
5. Portenoy R.K., Miransky J., Thaler H.T., et al. Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect. Cancer 70 6 (1992) 1616-1624
6. Twycross R., Harcourt J., and Bergl S. A survey of pain in patients with advanced cancer. J Pain Symptom Manage 12 5 (1996) 273-282
7. Twycross R.G., and Fairfield S. Pain in far-advanced cancer. Pain 14 3 (1982) 303-310
8. Cleeland C.S., Gonin R., Hatfield A.K., et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330 9 (1994) 592-596
9. Daut R.L., Cleeland C.S., and Flanery R.C. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17 2 (1983) 197-210
10. Melzack R. The short-form McGill pain questionnaire. Pain 30 2 (1987) 191-197
11. Caraceni A., and Portenoy R.K. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 82 3 (1999) 263-274
12. Caraceni A., and Weinstein S.M. Classification of cancer pain syndromes. Oncology (Huntingt) 15 12 (2001) 1627-1642 discussion 1642-1643, 1646-1647
13. Portenoy R.K. Cancer pain: pathophysiology and syndromes. Lancet 339 8800 (1992) 1026-1031
14. Cherny N.I., Thaler H.T., Friedlander-Klar H., et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies. Neurology 44 5 (1994) 857-861
15. Martin L.A., and Hagen N.A. Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies. J Pain Symptom Manage 14 2 (1997) 99-117
16. Stute P., Soukup J., Menzel M., Sabatowski R., and Grond S. Analysis and treatment of different types of neuropathic cancer pain. J Pain Symptom Manage 26 6 (2003) 1123-1131
17. Wilkie D.J., Huang H.Y., Reilly N., and Cain K.C. Nociceptive and neuropathic pain in patients with lung cancer: a comparison of pain quality descriptors. J Pain Symptom Manage 22 5 (2001) 899-910
18. Portenoy R.K. Pain and quality of life: clinical issues and implications for research. Oncology (Williston Park) 4 5 (1990) 172-178 discussion 194
19. Strang P., and Qvarner H. Cancer-related pain and its influence on quality of life. Anticancer Res 10 1 (1990) 109-112
20. Du Pen S.L., Du Pen A.R., Polissar N., et al. Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial. J Clin Oncol 17 1 (1999) 361-370
21. Klepstad P., Borchgrevink P.C., and Kaasa S. Effects on cancer patients' health-related quality of life after the start of morphine therapy. J Pain Symptom Manage 20 1 (2000) 19-26
22. Wong G.Y., Schroeder D.R., Carns P.E., et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 291 9 (2004) 1092-1099
23. Hwang S.S., Chang V.T., Fairclough D.L., and Kasimis B. Development of a cancer pain prognostic scale. J Pain Symptom Manage 24 4 (2002) 366-378
24. Rustøen T., Moum T., Padilla G., Paul S., and Miaskowski C. Predictors of quality of life in oncology outpatients with pain from bone metastasis. J Pain Symptom Manage 30 3 (2005) 234-242
25. Margolis R.B., Chibnall J.T., and Tait R.C. Test-retest reliability of the pain drawing instrument. Pain 33 1 (1988) 49-51
26. Margolis R.B., Tait R.C., and Krause S.J. A rating system for use with patient pain drawings. Pain 24 1 (1986) 57-65
27. Shi Q., Wang X.S., Mendoza T.R., Pandya K.J., and Cleeland C.S. Assessing persistent cancer pain: a comparison of current-pain ratings and pain recalled from the past week. J Pain Symptom Manage (2008) [Epub Aug 1, 2008]
28. Cleeland C.S., and Ryan K.M. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 23 2 (1994) 129-138
29. Graham C., Bond S.S., Gerkovich M.M., and Cook M.R. Use of the McGill pain questionnaire in the assessment of cancer pain: replicability and consistency. Pain 8 3 (1980) 377-387
30. Melzack R. The McGill pain questionnaire: major properties and scoring methods. Pain 1 3 (1975) 277-299
31. Chang V.T., Hwang S.S., and Kasimis B. Longitudinal documentation of cancer pain management outcomes: a pilot study at a VA medical center. J Pain Symptom Manage 24 5 (2002) 494-505
32. Portenoy R.K., Payne D., and Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81 1-2 (1999) 129-134
33. Bennett M.I., Attal N., Backonja M.M., et al. Using screening tools to identify neuropathic pain. Pain 127 3 (2007) 199-203
34. Galer B.S., and Jensen M.P. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 48 2 (1997) 332-338
35. Bennett M.I., Smith B.H., Torrance N., and Lee A.J. Can pain can be more or less neuropathic? Comparison of symptom assessment tools with ratings of certainty by clinicians. Pain 122 3 (2006) 289-294
36. Masson E.A., Hunt L., Gem J.M., and Boulton A.J. A novel approach to the diagnosis and assessment of symptomatic diabetic neuropathy. Pain 38 1 (1989) 25-28
37. Melzack R., Terrence C., Fromm G., and Amsel R. Trigeminal neuralgia and atypical facial pain: use of the McGill pain questionnaire for discrimination and diagnosis. Pain 27 3 (1986) 297-302
38. Mongini F., and Italiano M. TMJ disorders and myogenic facial pain: a discriminative analysis using the McGill pain questionnaire. Pain 91 3 (2001) 323-330
39. Mongini F., Italiano M., Raviola F., and Mossolov A. The McGill pain questionnaire in patients with TMJ pain and with facial pain as a somatoform disorder. Cranio 18 4 (2000) 249-256
40. Grushka M., and Sessle B.J. Applicability of the McGill pain questionnaire to the differentiation of 'toothache' pain. Pain 19 1 (1984) 49-57
41. Fernandez E., and Towery S. A parsimonious set of verbal descriptors of pain sensation derived from the McGill pain questionnaire. Pain 66 1 (1996) 31-37
42. Greene F.L., Page D.L., and Fleming I.D. AJCC cancer staging manual. 6th ed. (2002), Springer-Verlag, New York
43. Guy W. ECDEU assessment manual for psychopharmacology. DHEW Publication No. ADM 76-338 (1976), US Government Printing Office, Washington, DC
44. Dworkin R.H., Turk D.C., Farrar J.T., et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113 1-2 (2005) 9-19
45. Dunkl P.R., Taylor A.G., McConnell G.G., Alfano A.P., and Conaway M.R. Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 27 11 (2000) 2683-2691
46. Farrar J.T., Young Jr. J.P., LaMoreaux L., Werth J.L., and Poole R.M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94 2 (2001) 149-158
47. Caraceni A., Cherny N., Fainsinger R., et al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 23 3 (2002) 239-255
48. Hensing T.A., Peterman A.H., Schell M.J., Lee J.H., and Socinski M.A. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 98 4 (2003) 779-788
49. Cavaletti G., Bogliun G., Marzorati L., et al. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75 5 (1995) 1141-1150
50. Hilkens P.H., and ven den Bent M.J. Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst 2 4 (1997) 350-361
51. Quasthoff S., and Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 249 1 (2002) 9-17
52. Lipton R.B., Apfel S.C., Dutcher J.P., et al. Taxol produces a predominantly sensory neuropathy. Neurology 39 3 (1989) 368-373
53. Siegal T., and Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 66 6 (1990) 1117-1123
54. Streiner D.L.L., Norman G.R., and Norman G. Health measurement scales: a practical guide to their development and use (2003), Oxford Medical Publications, New York
55. Landis J.R., and Koch G.G. The measurement of observer agreement for categorical data. Biometrics 33 1 (1977) 159-174
56. Hochberg Y., and Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 9 7 (1990) 811-818
57. Bland J.M., and Altman D.G. Cronbach's alpha. BMJ 314 7080 (1997) 572
58. Turk D.C., Dworkin R.H., Burke L.B., et al. Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain 125 3 (2006) 208-215
59. Serlin R.C., Mendoza T.R., Nakamura Y., Edwards K.R., and Cleeland C.S. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61 2 (1995) 277-284
60. Paul S.M., Zelman D.C., Smith M., and Miaskowski C. Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints. Pain 113 1-2 (2005) 37-44
61. Cavaletti G., Bogliun G., Marzorati L., et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 61 9 (2003) 1297-1300
62. Cella D., Peterman A., Hudgens S., Webster K., and Socinski M.A. Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 98 4 (2003) 822-831